A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47

NCT02340208 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: L-DOS47

Sponsor

Helix BioPharma Corporation

Collaborators

[object Object]